

Amendments to the Drawings

Please replace Figures 1C and 1D with the Replacement Drawing Sheets accompanying this submission. The changes made in the Replacement Sheets are fully described in the Remarks Section of this Submission, and are noted on the Annotated Sheets included in the Appendix.

Attachments: Replacement Sheets for Figures 1C (11 sheets) and 1D (14 sheets)
Annotated Sheet Showing Changes to Figures 1C (11 sheets) and 1D (14 sheets)

Remarks

Status

The application has been placed in condition for allowance, except for formal matters which have to be resolved in order to put the specification into compliance with the sequence listing rules set forth in 37 C.F.R. §§1.821 – 1.825.

Prosecution on the merits is closed in accordance with the practice under *Ex parte Quayle*.

Claims 7, 8, 28 and 33-38 are allowable.

The Office Action mailed from the USPTO on May 5, 2009 indicates that upon Applicant's resolution of the formal matters indicated in the Office Action, the Examiners Amendment, which was attached to the Office Action will be entered into the record, and a Notice of Allowance will subsequently be issued.

Formal Matters Noted in the Office Action

The Office Action indicates that the disclosure of the instant application is rejected because "there are sequences disclosed in the specification and drawings which are not properly identified by sequence identification numbers" (Office Action, page 2). Furthermore, it is noted that the specification lists SEQ ID NOS: which are not currently present in the sequence listing which only contains 156 sequences. The Office Action indicates that Applicants should review the application in its entirety to ensure compliance with the sequence listing rules.

Amendments to the Specification

The above-mentioned amendments are made to insert the required SEQ ID NO identifiers assigned to numerous sequences that are disclosed in the specification, but which were not included in the original sequence listing.

The figure legends for Figures 1A and 1B have been amended to describe the sequences disclosed and the figures and to include SEQ ID NOS:.

The figure legends for Figures 1C and Figure 1D have been amended to indicate that the VL/FR sequences are set forth as consecutive framework segments (i.e., FR1, FR2, FR3 and FR4) and CDR (i.e., CDR1, CDR2 and CDR3) placeholders.

The amendment made on page 26, line 24 to page 27, line 21 of the specification are made to correct sequence discrepancies in SEQ ID NOS 311-337. Namely, the first two residues, "CA," were inserted into the sequences at the N-terminal. Support for said correction may be found in Figure 1D wherein the correct sequences are disclosed. No new matter has been added.

Paper and computer-readable copies of a Substitute Sequence Listing which includes all 443 sequences disclosed in the instant specification have been provided, along with an amendment requesting entry of the substitute sequence listing into the specification. In addition,

the paper and computer readable copies of the Sequence Listing is accompanied by a Statement indicating that the substitute sequence submitted herewith does not include new matter and that the content of the paper and computer-readable listings are the same.

Amendments to the Drawings

Amendments to the Drawings

Figure 1C

Replacement Sheets are provided for Figures 1C and 1D. The Figure 1C and 1D Replacement Sheets (11 sheets for Figure 1C and 14 sheets for Figure 1D) are included in the Appendix along with Annotated Sheets Showing Changes.

The first 5 sheets of Figure 1C (which comprises a total of 11 sheets) provide amino acid sequence information for various VL chains of selected anti-VEGF antibodies. As noted on the Annotated Sheets for Figure 1C, the replacement drawing includes a change to SEQ ID NO: 10 (which occurs on sheet 1 of Figure 1C). As noted in the annotated sheet accompanying this submission, this sequence was originally set forth as having an N-terminal "I" residue, however the correct N-terminal residue is "D." The replacement sheet sets forth the correct amino acid for SEQ ID NO: 10. The corrected sheet contains no new matter. Support for the corrected sequence can be found in the Sequence Listing which was filed with the application. No changes were made to the sequences disclosed on sheets 2-7.

The last 4 sheets (sheets 8-11) of Figure 1C provide amino acid sequence information for various VL/FRs of selected anti-VEGF antibodies. As noted above (in the Amendments to the Specification section) the Figure legend has been amended to indicate that the VL/FR sequences are set forth as consecutive framework segments (i.e., FR1, FR2, FR3 and FR4) and CDR (i.e., CDR1, CDR2 and CDR3) placeholders.

The format of last 4 sheets of Figure 1C has been amended to bring the disclosure into compliance with the sequence listing rules by providing each of the framework segments a unique SEQ ID NO:. Therefore, each of the frameworks set forth on sheets 7-11 of Figure 1C comprises 4 consecutive framework segments (i.e., FR1, FR2, FR3, and FR4) with intervening CDR regions occurring at the positions indicated by the placeholders (CDR1, CDR2 and CDR3). The text provided above each of the VL amino acid sequences has been amended to provide a list of SEQ ID NOS: comprising each of the disclosed VL framework sequences. No new matter was added by this amendment. The specification as filed provides support for the recitation of the terms FR1, FR2, FR3 and FR4 on page 64, lines 15-16.

Figure 1D

The first 9 sheets of Figure 1D (which comprises a total of 14 sheets) provide amino acid sequence information for various VH chains of selected anti-VEGF antibodies. The replacement sheets for Figure 1D include two amendments made to correct typographical errors. As indicated on page 3 of the annotated sheets, spaces were deleted from the beginning of SEQ ID NO:79 to make the sequence information begin at the left-justified margin. In addition, the format of the term "SEQ ID NO:" on sheet 4 of Figure 1D was corrected for SEQ ID NO: 90. The corrected sheets contain no new matter. No changes were made to sheets 1-2 and 5-12.


The last 2 sheets (sheets 13 and 14) of Figure 1D provide amino acid sequence information for various VH/FRs of selected anti-VEGF antibodies. As noted above the Figure legend has been amended to indicate that the VH/FR sequences are set forth as consecutive framework segments (i.e., FR1, FR2, FR3 and FR4) and CDR (ie., CDR1, CDR2 and CDR3) placeholders. The format of last 4 sheets of Figure 1D has been amended to bring the disclosure into compliance with the sequence listing rules by providing each of the framework sequences a unique SEQ ID NO:. Therefore, each of the frameworks set forth on sheets 13-14 of Figure 1D comprises 4 consecutive framework regions (i.e., FR1, FR2, FR3, and FR4) with intervening CDR regions occurring at the positions indicated by the placeholders (CDR1, CDR2 and CDR3). The text provided above each of the VH sequences has been amended to provide a list of SEQ ID NOS: comprising each of the disclosed VH framework sequences. No new matter was added by this amendment. The specification as filed provides support for the recitation of the terms FR1, FR2, FR3 and FR4 on page 64, lines 15-16.

Summary

For the reasons set forth hereinabove, Applicants believe that the present application is now in condition for allowance. Favorable reconsideration of the application as amended is respectfully requested. Applicants respectfully request that a timely Notice of Allowance be issued for this case.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone her at the number provided below.

Respectfully submitted,

By 

Patricia Chisholm
Reg. No. 45,822
Assistant Counsel

MERCK & CO., INC.
P.O. Box 2000
Rahway, New Jersey 07065-0907
(732) 594-5738

July 2, 2009



REPLACEMENT SHEETS

ANNOTATED SHEETS

Figure 1C

Amino Acid Sequences of V_L of Selected Anti-VZGF Antibodies

SEQ ID NO:1
DIQMTQSPSSLSASVGDRTVITCSASQDISNYLNNWYQQKPKGAPKVLIIYFTSSLHSGVPSRFSGGSGTDFTLTISSLPEDFATYYCQQYSTVPWTFGGQGTKVEIK

SEQ ID NO:2
DIELTQSPSSLSVSGDRVTISCSASQDISNYLNNWYQQKPKGAPRVLIYFTSSLHSGVPSRFSGGSGTDFTLTISSLPEDVAVYYCQQYSTVPWTFGGQGTKVEIK

SEQ ID NO:3
DIELTQSPSSLSVTPGERATITCSASQDISNYLNNWYQQKPKGAPQVLIYFTSSLHSGVPSRFSGGSGTDFTLTISSLQAEVAVYYCQQYSTVPWTFGGQGTKVEIK

SEQ ID NO:4
DIELTQSPSSLSVTPGERATITCSASQDISNYLNNWYQQKPKGAPQLIIYFTSSLHSGVPSRFSGGSGTDFTLTISSRLQAEVAVYYCQQYSTVPWTFGGQGTKVEIK

SEQ ID NO:5
DIEMTQSPSSLSASLGERVTISCSASQDISNYLNNWYQQKPKGAPHLLIIYFTSSLHSGVPSRFSGGSGTDFTLTISSLQAEVAVYYCQQYSTVPWTFGGQGTKVEIK

SEQ ID NO:6
DIVMTQSPSSLSATPGERVTITCSASQDISNYLNNWYQQKPKGAPRVLIYFTSSLHSGVPSRFSGGSGTDFTLTISSLPEDVAVYYCQQYSTVPWTFGGQGTKVEIK

SEQ ID NO:7
DIVMTQSPSSLSATPGERVTISCSASQDISNYLNNWYQQKPKGAPSLVYFTSSLHSGVPSRFSGGSGTDFTLTISSRLQAEVAVYYCQQYSTVPWTFGGQGTKVEIK

SEQ ID NO:8
DIVLTQSPSSLSATPGERVTITCSASQDISNYLNNWYQQKPKGAPQLIIYFTSSLHSGVPSRFSGGSGTDFTLTISSLQAEVAVYYCQQYSTVPWTFGGQGTKVEIK

SEQ ID NO:9
DIVLTQSPSSLSATPGERATITCSASQDISNYLNNWYQQKPKGAPHLLIIYFTSSLHSGVPSRFSGGSGTDFTLTISSLQAEVAVYYCQQYSTVPWTFGGQGTKVEIK

SEQ ID NO:10
DIEMTQSPSSLSATPGERVTITCSASQDISNYLNNWYQQKPKGAPRVLIYFTSSLHSGVPSRFSGGSGTDFTLTISSRLQAEVAVYYCQQYSTVPWTFGGQGTKVEIK

SEQ ID NO:11
DIEMTQSPSSLSVTPGERVTITCSASQDISNYLNNWYQQKPKGAPHLLIIYFTSSLHSGVPSRFSGGSGTDFTLTISSRLQAEVAVYYCQQYSTVPWTFGGQGTKVEIK

SEQ ID NO:12
DIELTQSPSSLSATLGERVTISCSASQDISNYLNNWYQQKPKGAPVLIYFTSSLHSGVPSRFSGGSGTDFTLTISSRLQAEVAVYYCQQYSTVPWTFGGQGTKVEIK

Inserted N-terminal "D" residue

Figure 1C-cont.

SEQ ID NO:13
DIEMTQSPSSLSASVGDRTVITCSASQDISNYLWYQQKPGQAPRVLIYFTSSLHSGVDPDRFSGSGSGTDFTLTISSLQAEDEFAVYYCQQYSTVPWTFGGGKVEIK

SEQ ID NO:14
DIQLTQSPSSLSASAGDRVTISCSASQDISNYLWYQQKPGKAPQLLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGGGKVEIK

SEQ ID NO:15
DIVMTQSPSSLSASPGERATISCNASQSIGTYLAWYQQKPGQAPQVLIYGASNLAGVPGRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSKRPWTFGGGKVEIK

SEQ ID NO:16
DIVMTQSPSSLSASPGERATISCRASQSISSYLAWYQQKPGQAPQVLIYGASNLAGVPNRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSSSPWTFGGGKVEIK

SEQ ID NO:17
DIVMTQSPSSLSASPGERATITCHASQSIGTYLAWYQQKPGQAPHVLIYGASNLAGVPNRFSGRSGTDFTLTISSLQPEDFATYYCQQYNSTPWTFFGGGKVEIK

SEQ ID NO:18
DIVMTQSPSSLSASPGERATITCHASQSI STYLAWYQQKPGQAPQVLIYDASNLAGVPGRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSAPWTFGGGKVEIK

SEQ ID NO:19
DIVMTQSPSSLSASPGERATITCKASQSIGTYLAWYQQKPGQAPRVLIYDASNLAGVPNRFSGRSGTDFTLTISSLQPEDFATYYCQQYSSTPYTFGGGKVEIK

SEQ ID NO:20
DIKMTQSPSSLSASPGERATISCKASQSIGSYLAWYQQKPGQAPSVLIYAAASNLAGVPNRFSGRSGTDFTLTISSLQPEDFATYYCQQYSGPWTFGGGKVEIK

SEQ ID NO:21
DIKMTQSPSSLSASPGERATITCNASQSI STYLAWYQQKPGQAPKVLIIYGASNLAGVPNRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSAPWTFGGGKVEIK

SEQ ID NO:22
DIVMTQSPSTLSASPGERATISCKASQSIGSYLAWYQQKPGQAPRVLIYSASNLAGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQYNSTPWTFFGGGKVEIK

SEQ ID NO:23
DIVMTQSPSTLSASPGERATISCKASQSIGTYLAWYQQKPGQAPRVLIYDASNLAGVPNRFSGRSGTDFTLTISSLQPEDFATYYCQQYYSTPWTFFGGGKVAIK

SEQ ID NO:24
DIVMTQSPSTLSASPGERATISCKASQSIGTYLAWYQQKPGQAPRVLIYSASNLAGVPNRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSSSTPWTFFGGGKVEIK

No changes

Figure 1C-cont.

SEQ ID NO:25
DIVMTQSPSTLSASPGERATITTCNASQSISSYLAWYQQKPGQAPNVLIIYGASNLAGVDPDRFSGSRSGTDFTLTISSLQPEDFAVYYCQQYNSTPWTFGGGTKVEIK

SEQ ID NO:26
DIVMTQSPSTLSASPGERATITTCNASQSISSYLAWYQQKPGQAPRVLIIYGASNLAGVDPDRFSGSRSGTDFTLTISSLQPEDFAVYYCQQYNSTPWTFGGGTKVEIK

SEQ ID NO:27
DIVMTQSPSTLSASPGERATITTCNASQSISSYLAWYQQKPGQAPQVLIYDASNLAGVDPDRFSGSRSGTDFTLTISSLQPEDFAVYYCQQYNSTPWTFGGGTKVEIK

SEQ ID NO:28
DIVMTQSPSTLSASPGERATITTCNASQSIGSYLAWYQQKPGQAPKVLIIYGASNLAGVDPDRFSGSRSGTDFTLTISSLQPEDFAVYYCQQYNSTPWTFGGGTKLEIK

SEQ ID NO:29
DIVMTQSPSTLSASPGERATITTCNASQSIGSYLAWYQQKPGQAPNLLIYDASNLAGVDPGRFSGSRSGTDFTLTISSLQPEDFAVYYCQQYSSTPWTFGGGTKVEIK

SEQ ID NO:30
DIVMTQSPSTLSASPGERATITTCNASQSIGSYLAWYQQKPGQAPNVLIIYDASNLAGVPSRFSGRSGTDFTLTISSLQPEDFAVYYCQQYYSAPWTFGGGTKVEIK

SEQ ID NO:31
DIVMTQSPSTLSASPGERATITTCNASQSISSYLAWYQQKPGQAPRVLIIYGASNLAGVPSRFSGRSGTDFTLTISSLQPEDFAVYYCQQYNSTPWTFGGGTKVEIK

SEQ ID NO:32
DIVMTQSPSTLSASPGERATITTCNASQSISSYLAWYQQKPGQAPKVLIIYDASNLAGVPSRFSGRSGTDFTLTISSLQPEDFAVYYCQQYNSTPWTFGGGTKVEIK

SEQ ID NO:33
DIVMTQSPSTLSASPGERATITTCNASQSISSYLAWYQQKPGQAPRLLIYASNLAGVPSRFSGRSGTDFTLTISSLQPEDFAVYYCQQYYSTPWTFGGGTKVEIK

SEQ ID NO:34
DIVMTQSPSTLSASPGERATITTCNASQSIGSYLAWYQQKPGQAPSVLIYGASNLAGVPSRFSGRSGTDFTLTISSLQAEDEFAVYYCQQYNSTPWTFGGGTKVEIK

SEQ ID NO:35
DIVMTQSPSTLSASPGERATITTCNASQSISSYLAWYQQKPGQAPQVLIYAASNLAGVPSRFSGRSGTDFTLTISSLQPEDFAVYYCQQYYSTPWTFGGGTKVEIK

SEQ ID NO:36
AIRMTPSSVSASVGDVTVTIACRASQAIRNDLTWYQQKPGTAPKLLIYGATTLQSGVPSRFSGRSGTDFTLTISSLQPEDFATYYCQQSSTPWTFGGGTKVDIK

SEQ ID NO:37
DIVMTQTPSSLSASVGDVTVTITCRASDIRNDLAWYQQKPGKAPPELLIYAASSLQSGVPSRFSGRSGTDFTLTISSLQPEDFATYYCQQSYSTPWTFGGGTKVDIK

No changes

Figure 1C-cont.

SEQ ID NO: 38
EIVLTQSPSSLSASIGDRVAITCRASRDITTDLAWYQQIPGKAPKLLIYAAASRLQSGVPSRFSGSGSGTDFTLTISLQPEDFAAYYCQQSYSTPWTFGQGTKVDIK

SEQ ID NO: 39
EIVLTQSPSSLSASVGDRTITTCRASDIRDDLAWYQQKPKGAPKVLIIYAASSLQSGVPSRFSGSGSGTDFTLTISLQPEDFAATYYCQQSYSTPWTFGQGTKLEIK

SEQ ID NO: 40
EIVLTQSPSSLSASVGDRTITTCRASQSIISTYINWYQQKPKGAPKLLIYAAASRLQSGVPSRFSGSGSGTDFTLTIRSLQPEDFAATYYCQQSYSTPWTFGQGTKVEIK

SEQ ID NO: 41
EIVMTQSPSSLSASVGDRTITTCRASQAIYDYLAWYQQKPKGAPNLLIYAAASRLQSGVPSRFSGSGSGTDFTLTISLQPEDFAATYYCQQSYSTPWTFGQGTKVDIK

SEQ ID NO: 42
EIVMTQSPSSLSASVGDRTITTCRASQDIRKDLAWYQQKPGIAPKVLIIYAASRLQSGVPSRFSGSGSGTDFTLTISLQPEDFAATYYCQQSYSTPWTFGQGTKLEIK

SEQ ID NO: 43
EIVMTQSPSSLSASVGDRTITTCRASQSIISTYINWYQQKPKGAPKLLIYAAASRLQSGVPSRFSGSGSGTDFTLTIRSLQPEDFAATYYCQQSYSTPWTFGQGTKVEIK

SEQ ID NO: 44
EIVMTQSPSSLSASVGDVTIACRASDIRNDLAWYQQKPKGAPKLLIYAAASRLQSGVPSRFSGTSGTDFTLTISLQPEDSASYCQQSYTIPWTFGQGTKLEIK

SEQ ID NO: 45
ETTLTQSPSSLSASVGDVTITISCRSSQPIITNDLAWYQQKPKGAPNLLIYAAASRLQSGVPSRFSGSGSGTDFTLTISLQPEDFAATYYCQQSYSTPWTFGQGTKVEIK

SEQ ID NO: 46
LPVLTQPPSASGTGPGQRTIISCSGTSNIGSNFVNWYQQLPGTAPKLLIYNNQRPSPGVDPDRFSGSKSGTSASLAISGLLSEDEADYYCASWDDSLTGYVFGTQTQL
TVL

SEQ ID NO: 47
LPVLTQPPSASGTGPGQRTIISCSGTSNIGSNVNWYQQLPGAAPKVLMTNNQRPSPGVDPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDSLNGYVFGTGTKL
TVL

SEQ ID NO: 48
NFMLTQPPSTSGTPGQRTIISCSGTSNIGSNSVTWYQQLPGTAPKVLMTNNQRPSPGVPERFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGYVFGTGTKL
TVL

SEQ ID NO: 49
QAVLTQPPSASGTGPGQSVTIISCSGTSNIGSNSVNWYQQLPGTAPKVLIIYNDQRPSPGVDPDRFSGSRSATASLAISGLQSEDEADYYCAAWDDSLSGYVFGAGTQL
TVL

No Changes

Figure 1C-cont.

SEQ ID NO: 50
QPVLTPPSASATPGQRTVITISCGSSSNIGSNPNVWYQQLPGTAPKVLIIYNNQRPVGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLSGYVFGTGTKL
TVL

SEQ ID NO: 51
QPVLTPPSASGTPGQRTVITISCGSSSNVGRNTVNWYQQFPGTAPKFLMYGNDERPSGVDPDRFSGSKSGTSASLAISGLQSEDEADYYCATWDDSLNGYVFGTGTL
TVL

SEQ ID NO: 52
QPVLTPPSTSGTPGQRTVITISCGSSSNIGSNVTWYQQLPGTAPKVLMTNNQRPVGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLSGYVFGTGTKL
TVL

SEQ ID NO: 53
QSVLTQPPSASGTPGQRTVITISCGSSSNIGSNNVWYQQFPGTAPKVLIIYGNQRPVGVPDRFSGSKSGTSASLAISGLQSEDEADYYCGAWDDSLNGYVFGTGTKL
TVL

SEQ ID NO: 54
QSALTQPPSVS GAPGQRTVITISCTGRSSNIGAGHDVHWYQQLPGTAPKLLIYANDQRPVGVPDRFSDSKSGTSASLGISGLRSEDEADYFCATWDDSLHGYYVFGTGK
VTVL

SEQ ID NO: 284
DIQMTQTSSLSASLGRVIIISCSASODISNVLNMYQOKPDGTVKVLIIYFTSSLSHSGVPSRFSGSGSGTDYSLTISNLEPEDIATYYCQQYSTVPWTFGGGKLEIK

No Changes

Figure 1C-cont.

Amino Acid Sequences of V_L/CDR1 of Selected Anti-VEGF Antibodies

SEQ ID NO: 164	NASQSIGTYLA
SEQ ID NO: 165	KASQSIGTYLA
SEQ ID NO: 166	HASQSISSYLA
SEQ ID NO: 167	SASQSISTYLA
SEQ ID NO: 168	RASQSISTYLA
SEQ ID NO: 169	KASQSIGSYLA
SEQ ID NO: 170	HASQSISTYLA
SEQ ID NO: 171	RASQSISSYLA
SEQ ID NO: 172	NASQSIGSYLA
SEQ ID NO: 173	SASQSIGTYLA
SEQ ID NO: 174	KASQSISTYLA
SEQ ID NO: 175	NASQSISTYLA
SEQ ID NO: 176	HASQSIGTYLA
SEQ ID NO: 177	QASQSISTYLA
SEQ ID NO: 178	RASQSIITYIN
SEQ ID NO: 179	RASRDIRNDLA
SEQ ID NO: 180	RASRDITDILA
SEQ ID NO: 181	RASQDIRKDLA
SEQ ID NO: 182	RASQAIRNDLT
SEQ ID NO: 183	RASQAITYDYLA
SEQ ID NO: 184	RSSQPTNDLA
SEQ ID NO: 185	RASRDIRDILA
SEQ ID NO: 186	SGSSSNVGRNTVN
SEQ ID NO: 187	SGTTSNIGSNPVN
SEQ ID NO: 188	TGRSSNIGAGHDVH
SEQ ID NO: 189	SGSNSNIGSNVY
SEQ ID NO: 190	SGYSNIGSNAVN
SEQ ID NO: 191	SGTTSNIGSNSVN
SEQ ID NO: 192	SGSSSNIGSNSVT
SEQ ID NO: 193	SGTTSNIGSNSVT
SEQ ID NO: 194	SGSSSNIGSNPVN

No Changes

Figure 1C-cont.

Amino Acid Sequences of V_L/CDR2 of Selected Anti-VEGF Antibodies

SEQ ID NO:195	GASNLAS
SEQ ID NO:196	DASNLAS
SEQ ID NO:197	SASNLAS
SEQ ID NO:204	AASNLAS
SEQ ID NO:198	AASSLQS
SEQ ID NO:199	AASRLQS
SEQ ID NO:200	AASTLQS
SEQ ID NO:201	GATTLQS
SEQ ID NO:202	AASRLQG
SEQ ID NO:203	GNDERPS
SEQ ID NO:205	ANDQRPS
SEQ ID NO:206	GNNQRPS
SEQ ID NO:207	TNNQRPS
SEQ ID NO:208	GNDQRPS
SEQ ID NO:209	SNNQRPS

Amino Acid Sequences of V_L/CDR3 of Selected Anti-VEGF Antibodies

SEQ ID NO:210	QQNSKPPWT
SEQ ID NO:211	QQYSTPYT
SEQ ID NO:212	QQYNSTPWT
SEQ ID NO:213	QQYSTPWT
SEQ ID NO:214	QQNSAPWT
SEQ ID NO:215	QQYSSSPWT
SEQ ID NO:216	QQYSGPWT
SEQ ID NO:217	QQYSTPWT
SEQ ID NO:218	QQYSAPWT
SEQ ID NO:219	QQYSTPWT
SEQ ID NO:220	QQYSPPWT
SEQ ID NO:221	QQYTIPWT
SEQ ID NO:222	QQSTTPWT
SEQ ID NO:223	ATWDDSLNGYV
SEQ ID NO:224	ASWDDSLTGYV
SEQ ID NO:225	ATWDDSLHGYV
SEQ ID NO:226	GAWDDSLNGYV
SEQ ID NO:227	AAWDDSLNGYV
SEQ ID NO:228	AAWDDSLSGYV

No Changes

Figure 1C-cont.

Amino Acid Sequences of V_H/FRs of Selected Anti-VEGF Antibodies

SEQ ID NOS 229 and 351-353 DIVMTQSPSSLSASPERATISIC/CDR1/WYQOKPGQAPQVLIY/CDR2/GVPGRFGSGSGTDFTLTISSLQPEDFAVYYC/CDR3/FGGGTKVEIK	Deleted: :
SEQ ID NOS 230, 354-355 and 353 DIVMTQSPSSLSASPERATITC/CDR1/WYQOKPGQAPRVLIY/CDR2/GVPNRFSGSRSGTDFTLTISSLQPEDFAVYYC/CDR3/FGGGTKVEIK	Deleted: :
SEQ ID NOS 231, 356-357 and 353 DIVMTQSPSTLSASPERATITC/CDR1/WYQOKPGQAPNVLIY/CDR2/GVPDRFGSRSGTDFTLTISSLQPEDFAVYYC/CDR3/FGGGTKVEIK	Deleted: :
SEQ ID NOS 232, 351, 355 and 353 DIVMTQSPSTLSASPERATITC/CDR1/WYQOKPGQAPQVLIY/CDR2/GVPNRFSGSRSGTDFTLTISSLQPEDFAVYYC/CDR3/FGGGTKVEIK	Deleted: :
SEQ ID NOS 233, 358, 355 and 353 DIVMTQSPSTLSASPERATITC/CDR1/WYQOKPGQAPRLLIY/CDR2/GVPNRFSGSRSGTDFTLTISSLQPEDFAVYYC/CDR3/FGGGTKVEIK	Deleted: :
SEQ ID NOS 234, 354, 359 and 353 DIVMTQSPSTLSASPERATISIC/CDR1/WYQOKPGQAPRVLIY/CDR2/GVPSRFGSRSGTDFTLTISSLQPEDFAVYYC/CDR3/FGGGTKVEIK	Deleted: :
SEQ ID NOS 235, 354, 360 and 353 DIVMTQSPSTLSASPERATITC/CDR1/WYQOKPGQAPRVLIY/CDR2/GVPNRFSGSGTDFTLTISSLQPEDFAVYYC/CDR3/FGGGTKVEIK	Deleted: :
SEQ ID NOS 236, 351, 360 and 353 DIVMTQSPSSLSASPERATISIC/CDR1/WYQOKPGQAPQVLIY/CDR2/GVPNRFSGSGTDFTLTISSLQPEDFAVYYC/CDR3/FGGGTKVEIK	Deleted: :
SEQ ID NOS 237, 361, 359 and 362 DIVMTQSPSTLSASPERATITC/CDR1/WYQOKPGQAPKVLII/CDR2/GVPSRFGSRSGTDFTLTISSLQPEDFAVYYC/CDR3/FGGGTKLEIK	Deleted: :
SEQ ID NOS 238, 363, 355 and 353 DIVMTQSPSSLSASPERATISIC/CDR1/WYQOKPGQAPSVLIY/CDR2/GVPNRFSGSRSGTDFTLTISSLQPEDFAVYYC/CDR3/FGGGTKVEIK	Deleted: :
SEQ ID NOS 239, 363-364 and 353 DIVMTQSPSTLSASPERATITC/CDR1/WYQOKPGQAPSVLIY/CDR2/GVPGRFGSGSGTDFTLTISSLQPEDFAVYYC/CDR3/FGGGTKVEIK	Deleted: :
SEQ ID NOS 240 and 351-353 DIVMTQSPSSLSASPERATITC/CDR1/WYQOKPGQAPQVLIY/CDR2/GVPGRFGSGSGTDFTLTISSLQPEDFAVYYC/CDR3/FGGGTKVEIK	Deleted: :

~~SEQ ID NOS~~ The Sequence Identifiers Listed Above in Blue Text were added to each of the Sequence Descriptions, and "s" were removed after the term "SEQ ID NOS."

Figure 1C-cont.

SEQ ID NOS 241, 351, 360 and 353 DIVMTQSPSTLSASGERATITC/CDR1/WYQOKPGQAPQVLLIY/CDR2/GVPNRFSGSGSGTDFTLTISLQPEDFAVYYC/CDR3/FGGGTKVEIK	Deleted: :
SEQ ID NOS 242, 354, 360 and 353 DIVMTQSPSTLSASGERATISC/CDR1/WYQOKPGQAPRVLLIY/CDR2/GVPNRFSGSGSGTDFTLTISLQPEDFAVYYC/CDR3/FGGGTKVEIK	Deleted: :
SEQ ID NOS 243, 354, 365 and 353 DIVMTQSPSTLSASGERATITC/CDR1/WYQOKPGQAPRVLLIY/CDR2/GVPNRFSGSGSGTDFTLTISLQPEDFAVYYC/CDR3/FGGGTKVEIK	Deleted: :
SEQ ID NOS 244, 366-367 and 353 DIVMTQSPSTLSASGERATITC/CDR1/WYQOKPGQAPNLLIY/CDR2/GVPGRFSGRSRSGTDFTLTISLQPEDFAVYYC/CDR3/FGGGTKVEIK	Deleted: :
SEQ ID NOS 245, 368-369 and 353 DIVMTQSPSTLSASGERATITC/CDR1/WYQOKPGQAPHVLLIY/CDR2/GVPNRFSGRSRSGTDFTLTISLQPEDFAVYYC/CDR3/FGGGTKVEIK	Deleted: :
SEQ ID NOS 246, 354-355 and 370 DIVMTQSPSTLSASGERATISC/CDR1/WYQOKPGQAPRVLLIY/CDR2/GVPNRFSGRSRSGTDFTLTISLQPEDFAVYYC/CDR3/FGGGTKVAIK	Deleted: :
SEQ ID NOS 247, 361 and 352-353 DIVMTQSPSTLSASGERATITC/CDR1/WYQOKPGQAPKLLIY/CDR2/GVPGRFSGSGSGTDFTLTISLQPEDFAVYYC/CDR3/FGGGTKVEIK	Deleted: :
SEQ ID NOS 248, 356, 359 and 353 DIVMTQSPSTLSASGERATITC/CDR1/WYQOKPGQAPNLLIY/CDR2/GVPNRFSGRSRSGTDFTLTISLQPEDFAVYYC/CDR3/FGGGTKVEIK	Deleted: :
SEQ ID NOS 249, 361, 360 and 353 DIVMTQSPSTLSASGERATITC/CDR1/WYQOKPGQAPKLLIY/CDR2/GVPNRFSGSGSGTDFTLTISLQPEDFAVYYC/CDR3/FGGGTKVEIK	Deleted: :
SEQ ID NOS 250 and 371-373 EIVMTQSPSTLSASVGDRTITC/CDR1/WYQOKPGKAPKLLIY/CDR2/GVTSRFSGSGSGTDFTLTIRSLQPEDFATYYC/CDR3/FGQGTKVEIK	Deleted: :
SEQ ID NOS 251 and 374-376 DIVMTQSPSTLSASVGDRTITC/CDR1/WYQOKPGKAPPELLIY/CDR2/GVPNRFSGSGSGTDFTLTISLQPEDFATYYC/CDR3/FGQGTKVDIK	Deleted: :
SEQ ID NOS 252, 377-378 and 376 EIVLTQSPSTLSASIGDRVAITC/CDR1/WYQOIIPGKAPKLLIY/CDR2/GVPNRFSGSGSGTDFTLTISLQPEDFAAAYC/CDR3/FGQGTKVDIK	Deleted: :
SEQ ID NOS 253 and 371-373 EIVLTQSPSTLSASVGDRTITC/CDR1/WYQOKPGKAPKLLIY/CDR2/GVTSRFSGSGSGTDFTLTIRSLQPEDFATYYC/CDR3/FGQGTKVEIK	Deleted: :

[Same Annotation as for sheet 8] The Sequence Identifiers Listed Above in Blue Text were added to each of the Sequence Descriptions and ";"s were removed after the term "SEQ ID NOS,"

Figure 1C-cont.

SEQ ID NOS 254, 379, 375 and 380 EIVMTQSPSSLSASVGDRTITC/CDR1/WYQOKPGIAPKVLII/CDR2/GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC/CDR3/FGQGTKLEIK	Deleted: :
SEQ ID NOS 255, 371, 381 and 380 EIVMTQSPSSLSASVGDRTITAC/CDR1/WYQOKPGKAPKLLII/CDR2/GVPSRFSGSGSGTDFALTISLQPEDSASYC/CDR3/FGQGTKLEIK	Deleted: :
SEQ ID NOS 256, 382 and 375-376 AIRMTQSPSSVSASVGDVTITAC/CDR1/WYQOKPGTAPKLLII/CDR2/GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC/CDR3/FGQGTKVDIK	Deleted: :
SEQ ID NOS 257, 383 and 375-376 EIVMTQSPSSLSASVGDRTITC/CDR1/WYQOKPGKAPNLLII/CDR2/GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC/CDR3/FGQGTKVDIK	Deleted: :
SEQ ID NOS 258, 383, 375 and 373 ETTLTQSPSSLSASVGDRTITSC/CDR1/WYQOKPGKAPNLLII/CDR2/GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC/CDR3/FGQGTKVEIK	Deleted: :
SEQ ID NOS 259, 384, 375 and 380 EIVLTQSPSSLSASVGDRTITC/CDR1/WYQOKPGKAPKVLII/CDR2/GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC/CDR3/FGQGTKLEIK	Deleted: :
SEQ ID NOS 260, 385, 375 and 373 DIQLTQSPSSLSASAGDRTITSC/CDR1/WYQOKPGKAPQLII/CDR2/GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC/CDR3/FGQGTKVEIK	Deleted: :
SEQ ID NOS 261 and 386-388 QPVLTPPSASGTPGQRTITSC/CDR1/WYQOPPGTAPKFLMY/CDR2/GVPDRFSGSKSGTSASLAISGLQSEDEADYYC/CDR3/FGTGTLTVL	Deleted: :
SEQ ID NOS 262, 389-390 and 388 LPVLTPPSASGTPGQRTITSC/CDR1/WYQQLPGTAPKLLII/CDR2/GVPDRLSGSKSGTSASLAISGLLSEDEADYYC/CDR3/FGTGTLTVL	Deleted: :
SEQ ID NOS 263, 389 and 391-392 QSALTQPPSVGAPGQRTITSC/CDR1/WYQQLPGTAPKLLII/CDR2/GVPDRFSDSKSGTSASLSISGLRSEDEADYFC/CDR3/FGTGTKVTVL	Deleted: :
SEQ ID NOS 264, 393, 387 and 394 QSVLTQPPSASGTPGQRTITSC/CDR1/WYQOPPGTAPKVLII/CDR2/GVPDRFSGSKSGTSASLAISGLQSEDEADYYC/CDR3/FGTGTKLTVL	Deleted: :
SEQ ID NOS 265, 395-396 and 394 LPVLTPPSASGTPGQRTITSC/CDR1/WYQQLPGAAPKVLMY/CDR2/GVPDRFSGSKSGTSASLAISGLRSEDEADYYC/CDR3/FGTGTKLTVL	Deleted: :
SEQ ID NOS 266 and 397-399 QAVLTQPPSASGTPGQSVTITSC/CDR1/WYQQLPGTAPKVLII/CDR2/GVPDRFSGSRSATSAISLAISGLQSEDEADYYC/CDR3/FGAGTQLTVL	Deleted: :

[same annotation as for sheet 8] The Sequence Identifiers Listed Above in Blue Text were added to each of the Sequence Descriptions, and "s" were removed after the term "SEQ ID NOS,"

Figure 1C-cont.

SEQ ID NOS 267, 400-401 and 394
QPVLTPPSTSGTPGQRTISC/CDR1/WYQQLPGTAPKVLMY/CDR2/GVPERFSGSKSGTSASLAISGLQSEDEADYYC/CDR3/FGTGTGKLTVL

Deleted: :

SEQ ID NOS 268, 400-401 and 394
NFMLTPPSTSGTPGQRTISC/CDR1/WYQQLPGTAPKVLMY/CDR2/GVPERFSGSKSGTSASLAISGLQSEDEADYYC/CDR3/FGTGTGKLTVL

Deleted: :

SEQ ID NOS 269, 397, 387 and 394
QPVLTPPSTSGTPGQRTISC/CDR1/WYQQLPGTAPKVLMY/CDR2/GVPERFSGSKSGTSASLAISGLQSEDEADYYC/CDR3/FGTGTGKLTVL

Deleted: :

[same annotation as for sheet 8] The Sequence Identifiers Listed Above in Blue Text were added to each of the Sequence Descriptions, and "s" were removed after the term "SEQ ID NOS."

Figure 1D

Amino Acid Sequences of V_H of Selected Anti-VEGF Antibodies

SEQ ID NO: 55
EVQLVESGGGLVQPGGSLRLSCAASGYFTFTNYGMNWVROAPGKGLEWVGWINTYTGPTYAADFRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYGSSH
WYFDVWGQGTLLTVVSS

SEQ ID NO: 56
EVQLVESGGGLVQPGGSLRLSCAASGYDFTHYGMNWVROAPGKGLEWVGWINTYTGPTYAADFRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYGTSH
WYFDVWGQGTLLTVVSS

SEQ ID NO: 57
EQQLVQSGGGVQPGGSLRLSCAASGYFTFTNYGMNWVROAPGKGLEWVGWINTYTGPTYAADFRRFTFSLDTSKSTAYLQNLNLSLRAEDTAVYYCAKYPHYGSSH
WYFDVWGQGTLLTVVSS

SEQ ID NO: 58
EVQLVESGGGVQPGGSLRLSCAASGYFTFTNYGMNWVROAPGKGLEWVGWINTYTGPTYAADFRRFTFSLDTSKSTAYLQMNLSQAYLQMNLSLRAEDTAVYYCAKYPHYGSSH
WYFDVWAQGTLLTVVSS

SEQ ID NO: 59
EVQLVQSGGGVQPGGTLRLSCAASGYFTFTNYGMNWVROAPGKGLEWVGWINTYTGPTYAADFRRFTFSLDTSKNTAYLQMNLSLRAEDTAVYYCAKYPHYGSSH
WYFDVWGQGTLLTVVSS

SEQ ID NO: 60
EVQLVQSGGGVQPGGSLRLRCAASGYFTFTNYGMNWVROAPGKGLEWVGWINTYTGPTYAADFRRFTFSLDTSKSTAYLQNLNLSLRAEDTAVYYCAKYPHYGSSH
WYFDVWGQGTLLTVVSS

SEQ ID NO: 61
EVQLVQSGGGVQPGGSLRLSCAASGDFFTNYGMNWVROAPGKGLEWVGWINTYTGPTYAADFRRFTFSLDTSKSTAYLQNLNLSLRAEDTAVYYCAKYPHYGSSH
WYFDVWGQGTLLTVVSS

SEQ ID NO: 62
EVQLVQSGGGVQPGGSLRLSCAASGYALDHFGLNWVROAPGKGLEWVGWINTYTGPTYAADFRRFTFSLDTSKSTAYLQNLNLSLRAEDTAVYYCAKYPHYGSSH
WYFDVWGQGTLLTVVSS

SEQ ID NO: 63
EVQLVQSGGGVQPGGSLRLSCAASGYDFYNYGINWVROAPGKGLEWVGWINTYTGPTYAHEFTRRVTFSLDTSKSTAYLQNLNLSLRAEDTAVYYCAKYPHYGSSH
WYFDVWGQGTLLTVVSS

No changes

Figure 1D-cont.

SEQ ID NO: 64
EVQLVQSGGIVQPQGSRLRLSCAASGYSLDHYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRVTFSLDTSKSTAYLQLNSLRAEDTAVYYCAKYPHYYGSSH
WYFDVWGQGTLLVTVSS

SEQ ID NO: 65
EVQLVQSGGIVQPQGSRLRLSCAASGYFTTNYGMNWIRQAPGKGLEWVGWINTYTGEPTYAADFKRRVTFSLDTSKNTAYLQLNSLRAEDTAVYYCAKYPHYYGSSH
WYFDVWGQGTLLVTVSS

SEQ ID NO: 66
EVQLVQSGGIVQPQGSRLRLSCAASGYFTTNYGMNWIRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTISLDNSKSTVYLQMNSLRAEDTAVYYCAKYPHYYGSSH
WYFDVWGQGTLLVTVSS

SEQ ID NO: 67
EVQLVQSGGIVQPQGSRLRLSCAASGYFTTNYGMNWIRQAPGKGLEWVGWINTYTGEPTYAADFKRRVTFSLDTSKSTAYLQLNSLRAEDTAVYYCAKYPHYYGSSH
WYFDVWGQGTLLVTVSS

SEQ ID NO: 68
EVQLVQSGGIVQPQGSRLRLSCAASGYFTTNYGMNWIRQAPGKGLEWVGWINTYTGEPTYAADFKRRVTFSLNTSKSTAYLQLNSLRAEDTAVYYCAKYPHYYGSSH
WYFDVWGQGTLLVTVSS

SEQ ID NO: 69
EVQLVQSGGIVQPQGSRLRLSCAASGYFTTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRVTFSLDTSKNTAYLQLNSLRAEDTAVYYCAKYPHYYGSSH
WYFDVWGQGTLLVTVSS

SEQ ID NO: 70
EVQLVQSGGIVQPQGSRLRLSCAASGYFTTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRVTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSH
WYFDVWGQGTLLVTVSS

SEQ ID NO: 71
EVQLVQSGGIVQPQGSRLRLTCAASGYFTTNYGMNWIRQAPGKGLEWVGWINTYTGEPTYAADFKRRVTFSLDNSKSTAYLQLNSLRAEDTAVYYCARYPHVYGSSH
WYFDVWGQGTLLVTVSS

SEQ ID NO: 72
EVQLVQSGGIVQPQGSRLRLTCAVSGYFTTNYGMNWIRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTISRDTSKNQAYLQMNSLRAEDTAVYYCAKYPHYYGSSH
WYFDVWGQGTLLVTVSS

No changes

Figure 1D-cont.

SEQ ID NO: 73
EVQLVQSGGTVQPGGTLRLTCAASGYTFFTNYGMNWIRQAPGKGLEWVGWINTYTGPTYAADFRRRTFSLDTSKSTAYLQNLNRAEDTAVYYCAKYPHYGSSH
WYFDVWGQGTLLTVVSS

SEQ ID NO: 74
EVQLVQSGGTVQPGGTLRLTCAASGYTFFTNYGMNWIRQAPGKGLEWVGWINTYTGPTYAADFRRRTFSLDTSKSTAYLQNLNRAEDTAVYYCAKYPHYGSSH
WYFDVWGQGTLLTVVSS

SEQ ID NO: 75
EVQLVQSGGTVQPGGTLRLTCAASGYTFFTNYGMNWIRQAPGKGLEWVGWINTYTGPTYAADFRRRTFSLDTSKSTAYLQNLNRAEDTAVYYCAKYPHYGSSH
WYFDVWGQGTLLTVVSS

SEQ ID NO: 76
EVQLVQSGGTVQPGGTLRLTCAASGYTFFTNYGMNWIRQAPGKGLEWVGWINTYTGPTYAADFRRRTFSLDTSKSTVYLQMNLSRAEDTAVYYCAKYPHYGSSH
WYFDVWGQGTLLTVVSS

SEQ ID NO: 77
QVQLVQSGGTVQPGGTLRLTCAASGYTFFTNYGMNWIRQAPGKGLEWVGWINTYTGPTYAADFRRRTFSLDTSKSKAYLQNLNRAEDTAVYYCARYPHYVGGSSH
WYFDVWGQGTLLTVVSS

SEQ ID NO: 78
QVQLVQSGGTVQPGGTLRLTCAASGYTFFTNYGMNWIRQAPGKGLEWVGWINTYTGPTYAADFRRRTFSLDTSKNPPYLQMNLSRAEDTAVYYCAKYPHYVGGSSH
WYFDVWGQGTLLTVVSS

SEQ ID NO: 79
QVQLVQSGGTVQPGGTLRLTCAASGYTFFTNYGMNWIRQAPGKGLEWVGWINTYTGPTYAADFRRRTFSLDTSKSTVYLQMNLSRAEDTAVYYCAKYPHYVGGSSH
WYFDVWGQGTLLTVVSS

SEQ ID NO: 80
QVQLVQSGGTVQPGGTLRLTCAASGYTFFTNYGMNWIRQAPGKGLEWVGWINTYTGPTYAADFRRRTFSLDTSKNTAYLQNLNRAEDTAVYYCAKYPHYVGGSSH
WYFDVWGQGTLLTVVSS

SEQ ID NO: 81
QVQLVQSGGTVQPGGTLRLTCAASGYTFFTNYGMNWIRQAPGKGLEWVGWINTYTGPTYAADFRRRTFSLDTSKSQAYLQMNLSRAEDTAVYYCAKYPHYVGGSSH
WYFDVWGQGTLLTVVSS

SEQ ID NO: 82
QVQLVQSGGTVQPGGTLRLTCAASGYTFFTNYGMNWIRQAPGKGLEWVGWINTYTGPTYAADFRRRTFSLDTSKSTAYLQNLNRAEDTAVYYCAKYPHYVGGSSH
WYFDVWGQGTLLTVVSS

Deleted: SPACES

Figure 1D-cont.

SEQ ID NO: 83
QVQLVQSGGIVQPGGSLRLTCAASGYTFITNYGMNWIRQAPGKGLEWVGWINTYTGEPYAADFKRRFTISLDTSKSOAYLQMNSLRAEDTAVYYCAKYPHYVYSS
WYFDVWGQGLTVTVSS

SEQ ID NO: 84
QVQLVQSGGIVQPGGSLRLTCAASGYTFITNYGMNWIRQAPGKGLEWVGWINTYTGEPYAADFKRRFTISLDTSKNTAYLQMNSLRAEDTAVYYCAKYPHYVYSS
WYFDVWGQGLTVTVSS

SEQ ID NO: 85
EVQLVQSGGIVQPGGSLRLSCAASGYTFTHYGLNWIRQAPGKGPWVGWVNTYTGETTYADEFKRRVTFSLDTSKSTAYLQNLNLAEDTAVYYCAKYPHYVYSS
WYFDVWGQGLTVTVSS

SEQ ID NO: 86
EVQLVQSGGIVQPGGSLRLSCAASGFNTHYGINWIRQAPGKGPWVGWINTNNGEPTYAQDFKRRVTFSLDTSKSTAYLQNLNLAEDTAVYYCAKYPHYVYSS
WYFDVWGQGLTVTVSS

SEQ ID NO: 87
EVQLVQSGGIVQPGGSLRLSCAASGYDFAHYGLNWIRQAPGKGLEWVGWVNTYTGESTYVPEFKRRVTFSLDTSKSTAYLQNLNLAEDTAVYYCAKYPHYVYSS
WYFDVWGQGLTVTVSS

SEQ ID NO: 88
EVQLVQSGGIVQPGGSLRLSCAASGYDFAHYGVNWIRQAPGKGLEWVGWINTYTGETTYAHDFKRRVTFSLDTSKSTAYLQNLNLAEDTAVYYCAKYPHYVYSS
WYFDVWGQGLTVTVSS

SEQ ID NO: 89
EVQLVQSGGIVQPGGSLRLSCAASGYDFAFGINWIRQAPGKGLEWVGWINTYTGESTYAQDFKRRVTFSLDTSKSTAYLQNLNLAEDTAVYYCAKYPHYVYSS
WYFDVWGQGLTVTVSS

SEQ ID NO: 90
EVQLVQSGGIVQPGGSLRLSCAASGYDFHFGINWIRQAPGKGPWVGWINTYTGETTYVDFKRRVTFSLDTSKSTAYLQNLNLAEDTAVYYCAKYPHYVYSS
WYFDVWGQGLTVTVSS

SEQ ID NO: 91
EVQLVQSGGIVQPGGSLRLSCAASGYDFNNGINWIRQAPGKGPWVGWINTYNGEPTYAPDFKRRVTFSLDTSKSTAYLQNLNLAEDTAVYYCAKYPHYVYSS
WYFDVWGQGLTVTVSS

~~Figure 1D~~ Corrected typographical error to change "SEQ 90" to "SEQ ID NO: 90"

Figure 1D-cont.

SEQ ID NO:92
EVQLVQSGGAVQPGGSLRLSCAASGYDFSHFGINWIRQAPGKGLEWVGWINTYTGETTYAHDFKRRVTFSLDTSKSTAYLQLNSLRAEDTAVYYCAKYPYYGRSH
WYFDVWGQGTLLVTVSS

SEQ ID NO:93
EVQLVQSGGAVQPGGSLRLSCAASGYDFSHFGINWVRQAPGKGPWVGWINTYTGETTYVPEFKRRVTFSLDTSKSTAYLQLNSLRAEDTAVYYCAKYPYYGRSH
WYFDVWGQGTLLVTVSS

SEQ ID NO:94
EVQLVQSGGAVQPGGSLRLSCAASGYDFSNYGLNWVRQAPGKGPWVGWINTYTGETTYAEFTRRVTFSLDTSKSTAYLQLNSLRAEDTAVYYCAKYPYYGRSH
WYFDVWGQGTLLVTVSS

SEQ ID NO:95
EVQLVQSGGAVQPGGSLRLSCAASGYDFTHYGLNWIRQAPGKGPWVGWINTYTGETTYAHEFTRRVTFSLDTSKSTAYLQLNSLRAEDTAVYYCAKYPYYGRSH
WYFDVWGQGTLLVTVSS

SEQ ID NO:96
EVQLVQSGGAVQPGGSLRLSCAASGYNFHYGVNWVRQAPGKGPWVGWNTYTGETTYAQEFKRRVTFSLDTSKSTAYLQLNSLRAEDTAVYYCAKYPYYGRSH
WYFDVWGQGTLLVTVSS

SEQ ID NO:97
EVQLVQSGGAVQPGGSLRLSCAASGYNFYSYGLNWVRQAPGKGPWVGWINTYTGETTYAQEFKRRVTFSLDTSKSTAYLQLNSLRAEDTAVYYCAKYPYYGRSH
WYFDVWGQGTLLVTVSS

SEQ ID NO:98
EVQLVQSGGAVQPGGSLRLSCAASGYSFHDYGLNWVRQAPGKGLEWVGWINTYTGETTYADEFTRRVTFSLDTSKSTAYLQLNSLRAEDTAVYYCAKYPYYGRSH
WYFDVWGQGTLLVTVSS

SEQ ID NO:99
EVQLVQSGGAVQPGGSLRLSCAASGYFTTNYGMNWIRQAPGKGLEWVGWINTYTGETTYAADFTRRVTFSLDTSKSTAYLQLNSLRAEDTAVYYCAKYPYYGRSH
WYFDVWGQGTLLVTVSS

SEQ ID NO:100
EVQLVQSGGAVQPGGSLRLSCAASGYFTTNYGMNWIRQAPGKGLEWVGWINTYTGETTYAADFKRRVTFSLDTSKSTAYLQLNSLRAEDTAVYYCAKYPYYGRSH
WYFDVWGQGTLLVTVSS

SEQ ID NO:101
EVQLVQSGGAVQPGGSLRLSCAASGYFTTNYGMNWVRQAPGKGLEWVGWINTYTGETTYAADFKRRPFTFSLDTSKSTAYLQMNLSLRAEDTAVYYCAKYPYYGRSH
WYFDVWGQGTLLVTVSS

No Changes

Figure 1D-cont.

SEQ ID NO:102
EVQLVQSGGGLVQPGGSLRLSCAASGYTFSTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFRRRTFSLDTSKSTAYLQMNLSLRAEDTAVVYCAKYPYYGRSH
WYFDVWGQGLTVTVSS

SEQ ID NO:103
EVQLVESGGGLVQPGGSLRLSCAASGYTFSTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFRRRTFSLDTSKSTAYLQMNLSLRAEDTAVVYCAKYPYYGTSH
WYFDVWGQGLTVTVSS

SEQ ID NO:104
EVQLVESGGGLVQPGGSLRLSCAASGYTFSTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFRRRTFSLDTSKSTAYLQMNLSLRAEDTAVVYCAKYPHYGRSH
WYFDVWGQGLTVTVSS

SEQ ID NO:105
EVQLVESGGGLVQPGGSLRLSCAASGYTFSTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFRRRTFSLDTSKSTAYLQMNLSLRAEDTAVVYCAKYPYYGRSH
WYFDVWGQGLTVTVSS

SEQ ID NO:106
EVQLVQSGGGLVQPGGSLRLSCAASGYDFTHFGLNWIRQAPGKGPWVGWINTYTGEPTYAQDFKRRVTFSLDTSKSTAYLQNLNSLRAEDTAVVYCAKYPYYGRSH
WYFDVWGQGLTVTVSS

SEQ ID NO:107
EVQLVQSGGGLVQPGGSLRLSCAASGYDLSHYGLNWIRQAPGKGPWVGWINTYTGEPTYAPDFTRRVTFSLDTSKSTAYLQNLNSLRAEDTAVVYCAKYPYYGRSH
WYFDVWGQGLTVTVSS

SEQ ID NO:108
EVQLVQSGGGLVQPGGSLRLSCAASGYNFSHFGLNWLRLQAPGKGLEWVGWINTYNGETTYAPDFKRRVTFSLDTSKSTAYLQNLNSLRAEDTAVVYCAKYPYYGRSH
WYFDVWGQGLTVTVSS

SEQ ID NO:109
EVQLVQSGGGLVQPGGSLRLSCAASGYNFSHFGLNWLRLQAPGKGPWVGWINTYTGEPTYAPEFKRRVTFSLDTSKSTAYLQNLNSLRAEDTAVVYCAKYPYYGRSH
WYFDVWGQGLTVTVSS

SEQ ID NO:110
EVQLVQSGGGLVQPGGSLRLSCAASGYDFTHFGLNWVRQAPGKGLEWVGWINTYTGETTYAHEFKRRVTFSLDTSKSTAYLQNLNSLRAEDTAVVYCAKYPYYGRSH
WYFDVWGQGLTVTVSS

No Changes

Figure 1D-cont.

SEQ ID NO:283
EIQLVQSGPELKQPGETVRI~~SCASGYTFTNYGMNWVRQA~~PGKGLKWMGWINTYTGEPTVAADF~~KRRFTFSLETSASTAYLQISNLKND~~DDTATYFCAKYPHYYGSSH
WYFDVWGAGTTVTVSS

SEQ ID NO:285
EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTVAADF~~KRRFTFS~~LDTSKSTAYLQMNSLRAEDTAVVYCAHSRHHYGGSSP
QYFDV WCQGT~~LVTVSS~~

SEQ ID NO:286
EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTVAADF~~KRRFTFS~~LDTSKSTAYLQMNSLRAEDTAVVYCAKYGYYYGSSH
WYFDVWGQGT~~LVTVSS~~

SEQ ID NO:287
EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTVAADF~~KRRFTFS~~LDTSKSTAYLQMNSLRAEDTAVVYCAKYPHYYGASH
WYFDVWGQGT~~LVTVSS~~

SEQ ID NO:288
EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTVAADF~~KRRFTFS~~LDTSKSTAYLQMNSLRAEDTAVVYCAKYPHYYGCH
WYFDVWGQGT~~LVTVSS~~

SEQ ID NO:289
EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTVAADF~~KRRFTFS~~LDTSKSTAYLQMNSLRAEDTAVVYCAKYPHYYGSH
WYFDVWGQGT~~LVTVSS~~

SEQ ID NO:290
EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTVAADF~~KRRFTFS~~LDTSKSTAYLQMNSLRAEDTAVVYCAKYPHYYGYN
QYFDVWGQGT~~LVTVSS~~

SEQ ID NO:291
EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTVAADF~~KRRFTFS~~LDTSKSTAYLQMNSLRAEDTAVVYCAKYPHYGRSH
WYFDVWGQGT~~LVTVSS~~

SEQ ID NO:293
EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTVAADF~~KRRFTFS~~LDTSKSTAYLQMNSLRAEDTAVVYCAKYPHYGRSQ
WYLDVWGQGT~~LVTVSS~~

No Changes

Figure 1D-cont.

SEQ ID NO:294
EVQLVESGGGLVQPGGSLRLSCAASGYTFFTNYGMNWVRQAPGKGLEWVGWINTYTGPTYAADFRRRTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYSRTC
QYFDVWGQGTLLVTVSS

SEQ ID NO:295
EVQLVESGGGLVQPGGSLRLSCAASGYTFFTNYGMNWVRQAPGKGLEWVGWINTYTGPTYAADFRRRTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYSSSH
WYFDVWGQGTLLVTVSS

SEQ ID NO:296
EVQLVESGGGLVQPGGSLRLSCAASGYTFFTNYGMNWVRQAPGKGLEWVGWINTYTGPTYAADFRRRTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPFYGSSH
WYFDVWGQGTLLVTVSS

SEQ ID NO:297
EVQLVESGGGLVQPGGSLRLSCAASGYTFFTNYGMNWVRQAPGKGLEWVGWINTYTGPTYAADFRRRTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYHGHSSH
WYFDVWGQGTLLVTVSS

SEQ ID NO:298
EVQLVESGGGLVQPGGSLRLSCAASGYTFFTNYGMNWVRQAPGKGLEWVGWINTYTGPTYAADFRRRTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYNGSSH
WYFDVWGQGTLLVTVSS

SEQ ID NO:299
EVQLVESGGGLVQPGGSLRLSCAASGYTFFTNYGMNWVRQAPGKGLEWVGWINTYTGPTYAADFRRRTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYNSTSH
WYFDVWGQGTLLVTVSS

SEQ ID NO:300
EVQLVESGGGLVQPGGSLRLSCAASGYTFFTNYGMNWVRQAPGKGLEWVGWINTYTGPTYAADFRRRTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYSGTSH
WYFDVWGQGTLLVTVSS

SEQ ID NO:301
EVQLVESGGGLVQPGGSLRLSCAASGYTFFTNYGMNWVRQAPGKGLEWVGWINTYTGPTYAADFRRRTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYSGTSH
WYFDVWGQGTLLVTVSS

SEQ ID NO:302
EVQLVESGGGLVQPGGSLRLSCAASGYTFFTNYGMNWVRQAPGKGLEWVGWINTYTGPTYAADFRRRTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYGRSH
WYFDVWGQGTLLVTVSS

SEQ ID NO:303
EVQLVESGGGLVQPGGSLRLSCAASGYTFFTNYGMNWVRQAPGKGLEWVGWINTYTGPTYAADFRRRTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYGGSSH
WYFDVWGQGTLLVTVSS

No Changes

Figure 1D-cont.

SEQ ID NO: 304
EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYYGSSS
WYFDVWGQGTLLTVTSS

SEQ ID NO: 305
EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYYSTSH
WYFDVWGQGTLLTVTSS

SEQ ID NO: 306
EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYRDFNGSSH
WYFDVWGQGTLLTVTSS

SEQ ID NO: 307
EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYSYYGSSH
WYFDVWGQGTLLTVTSS

SEQ ID NO: 308
EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCARARHYGSSH
CYFDLWGQGTLLTVTSS

SEQ ID NO: 309
EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCARDSHYYGSSH
QYFDLWGQGTLLTVTSS

SEQ ID NO: 310
EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYGTSH
WYFDVWGQGTLLTVTSS

N. Changes

Figure 1D-cont.

Amino Acid Sequences of V_H/CDR1 of Selected Anti-VEGF Antibodies

SEQ ID NO: 111	GFDF ² NYGMN
SEQ ID NO: 112	GYTF ² NYGMN
SEQ ID NO: 113	GYSLDHYGMN
SEQ ID NO: 114	GYALDHFGLN
SEQ ID NO: 115	GYDFYNYGIN
SEQ ID NO: 116	GYTF ² NYGMN
SEQ ID NO: 117	GYSF ² DHYGLN
SEQ ID NO: 118	GYDFS ² NYGLN
SEQ ID NO: 119	GYDFS ² HFGIN
SEQ ID NO: 120	GYDFAHYGVN
SEQ ID NO: 121	GYDFD ² HFGIN
SEQ ID NO: 122	GYDFN ² NYGMN
SEQ ID NO: 123	GYDFA ² SFGIN
SEQ ID NO: 124	GFNF ² THYGIN
SEQ ID NO: 125	GYDFAHYGLN
SEQ ID NO: 126	GYNFYHYGVN
SEQ ID NO: 127	GYDF ² THYGLN
SEQ ID NO: 128	GYNFY ² SYGLN
SEQ ID NO: 129	GYDFS ² HFGIN
SEQ ID NO: 130	GYTF ² THYGLN
SEQ ID NO: 131	GYDFT ² HFGIN
SEQ ID NO: 132	GYDL ² SHYGLN
SEQ ID NO: 133	GYNF ² SHFGIN
SEQ ID NO: 134	GYNF ² SHFGIN
SEQ ID NO: 135	GYDFT ² HFGIN

No Changes

Figure 1D-cont.

Amino Acid Sequences of V_H/CDR2 of Selected Anti-VEGF Antibodies

SEQ ID NO: 136	WINTYTGEPITYAHEFTR
SEQ ID NO: 137	WINTYTGEPITYAADFTR
SEQ ID NO: 138	WINTYTGEPITYADEFTR
SEQ ID NO: 139	WINTYTGEPITYAEEFTR
SEQ ID NO: 140	WINTYTGEPITYVPEFTR
SEQ ID NO: 141	WINTYTGEPITYAHDFR
SEQ ID NO: 142	WINTYTGEPITYVDFR
SEQ ID NO: 143	WINTYNGEPITYAPDFR
SEQ ID NO: 144	WINTYTGESTYAQDFR
SEQ ID NO: 145	WINTNNGEPITYAQDFR
SEQ ID NO: 146	WNTYTGESTYVPEFR
SEQ ID NO: 147	WNTYTGEPITYAQEFTR
SEQ ID NO: 148	WINTYTGEPITYAHEFTR
SEQ ID NO: 149	WINTYTGEPITYAQEFTR
SEQ ID NO: 150	WINTYTGEPITYAHDFR
SEQ ID NO: 151	WNTYTGEPITYADEFR
SEQ ID NO: 152	WINTYTGEPITYAQDFR
SEQ ID NO: 153	WINTYTGEPITYAPDFTR
SEQ ID NO: 154	WINTYNGEPITYAPDFR
SEQ ID NO: 155	WINTYTGEPITYAPEFR
SEQ ID NO: 156	WNTYTGEPITYAHEFR

No Changes

Figure 1D-cont.

Amino Acid Sequences of V_H/CDR3 of Selected Anti-VEGF Antibodies

SEQ ID NO:311	CAHSRHYVGSSSPQYFDV
SEQ ID NO:312	CAKYGYVYGSSSHWYFDV
SEQ ID NO:313	CAKYPHYYGASHWYFDV
SEQ ID NO:314	CAKYPHYVGGCHWYFDV
SEQ ID NO:315	CAKYPHYVGGSHWYFDV
SEQ ID NO:316	CAKYPHYVGGYNQYFDV
SEQ ID NO:317	CAKYPHYVGRSHWYFDV
SEQ ID NO:318	CAKYPHYVGRSQWYLDV
SEQ ID NO:319	CAKYPHYVSRTCQYFDV
SEQ ID NO:320	CAKYPHYVSSSHWYFDV
SEQ ID NO:321	CAKYPFVYGSSSHWYFDV
SEQ ID NO:322	CAKYPYVHGSSSHWYFDV
SEQ ID NO:323	CAKYPYVNGSSSHWYFDV
SEQ ID NO:324	CAKYPYVNSTSHWYFDV
SEQ ID NO:325	CAKYPYVSGTSHWYFDV
SEQ ID NO:326	CAKYPYVSGTSHWYFDY
SEQ ID NO:327	CAKYPYVYGRSHWYFDV
SEQ ID NO:328	CAKYPYVYGGSSSHWYFDV
SEQ ID NO:329	CAKYPYVYGGSSSWYFDV
SEQ ID NO:330	CAKYPYVYSTSHWYFDV
SEQ ID NO:331	CAKYRDFNGSSSHWYFDV
SEQ ID NO:332	CAKYSYVYGSSSHWYFDV
SEQ ID NO:333	CARARHYVGSSSHCYFDL
SEQ ID NO:334	CARDSHYVYGSSSHQYFDL
SEQ ID NO:335	CAKYPHYVGTSHWYFDV
SEQ ID NO:336	CAKYPHYVYGSSSHWYFDV
SEQ ID NO:337	CAKYPYVYGTSHWYFDV

No Changes

Figure 1D-cont.

Amino Acid Sequences of V_H/FRs of Selected Anti-VEGF Antibodies

SEQ ID NOS <u>157</u> and <u>402-404</u> EVQLVQSGGGVVPGGSLRLSCAAS/CDR1/WVRQAPGKGLEWVG/CDR2/RFTFSLDTSKSTAYLQMNSLRAEDTAVYYCA/CDR3/WGQGTLLVTSS	Deleted: :
SEQ ID NOS <u>158</u> , <u>402</u> , <u>405</u> and <u>404</u> EVQLVQSGGGVVPGGSLRLSCAAS/CDR1/WVRQAPGKGLEWVG/CDR2/RFTFSLDTSKNTAYLQLNSLRAEDTAVYYCA/CDR3/WGQGTLLVTSS	Deleted: :
SEQ ID NOS <u>159</u> , <u>406-407</u> and <u>404</u> EVQLVQSGGGVVPGGSLRLSCAAS/CDR1/WIRQAPGKGLEWVG/CDR2/RFTISLDNSKSTVYLQMNSLRAEDTAVYYCA/CDR3/WGQGTLLVTSS	Deleted: :
SEQ ID NOS <u>160</u> , <u>406</u> , <u>408</u> and <u>404</u> EVQLVQSGGGVVPGGSLRLTCAVS/CDR1/WIRQAPGKGLEWVG/CDR2/RFTISRDTSKNQAYLQMNSLRAEDTAVYYCA/CDR3/WGQGTLLVTSS	Deleted: :
SEQ ID NOS <u>161</u> , <u>406</u> , <u>409</u> and <u>404</u> EVQLVQSGGGVVPGGSLRLSCAAS/CDR1/WIRQAPGKGLEWVG/CDR2/RVTFSLDTSKSTAYLQLNSLRAEDTAVYYCA/CDR3/WGQGTLLVTSS	Deleted: :
SEQ ID NOS <u>162</u> , <u>402</u> , <u>410</u> and <u>404</u> QVQLVQSGGGVVPGGSLRLTCAAS/CDR1/WVRQAPGKGLEWVG/CDR2/RFTISLDTSKSQAYLQMNSLRAEDTAVYYCA/CDR3/WGQGTLLVTSS	Deleted: :
SEQ ID NOS <u>163</u> , <u>402</u> , <u>411</u> and <u>404</u> EVQLVQSGGGVVPGGTLRLTCAAS/CDR1/WVRQAPGKGLEWVG/CDR2/RVTFSLDTSKSTAYLQMNSLRAEDTAVYYCA/CDR3/WGQGTLLVTSS	Deleted: :
SEQ ID NOS <u>270</u> , <u>406</u> and <u>412-413</u> EVQLVESGGGVVPGGSLRLSCAAS/CDR1/WIRQAPGKGLEWVG/CDR2/RFTISLDNSKSQAYLQMNSLRAEDTAVYYCA/CDR3/WAQGTLLVTSS	Deleted: :
SEQ ID NOS <u>271</u> , <u>406</u> , <u>414</u> and <u>404</u> EVQLVQSGGGVVPGGTLRLSCAAS/CDR1/WIRQAPGKGLEWVG/CDR2/RFTFSLDTSKNTAYLQMNSLRAEDTAVYYCA/CDR3/WGQGTLLVTSS	Deleted: :
SEQ ID NOS <u>272</u> , <u>406</u> , <u>409</u> and <u>404</u> EVQLVQSGGGVVPGGSLRLRCAAS/CDR1/WIRQAPGKGLEWVG/CDR2/RVTFSLDTSKSTAYLQLNSLRAEDTAVYYCA/CDR3/WGQGTLLVTSS	Deleted: :
SEQ ID NOS <u>273</u> , <u>406</u> , <u>405</u> and <u>404</u> EVQLVQSGGGVVPGGSLRLSCAAS/CDR1/WIRQAPGKGLEWVG/CDR2/RFTFSLDTSKNTAYLQLNSLRAEDTAVYYCA/CDR3/WGQGTLLVTSS	Deleted: :
SEQ ID NOS <u>274</u> , <u>406</u> , <u>409</u> and <u>404</u> EVQLVQSGGGVVPGGTLRLSCAAS/CDR1/WIRQAPGKGLEWVG/CDR2/RVTFSLDTSKSTAYLQLNSLRAEDTAVYYCA/CDR3/WGQGTLLVTSS	Deleted: :

The sequence Identifiers Listed Above in Blue Text were added to each of the sequence descriptions and "g"s were removed after the term "SEQ ID NOS."

Figure 1D-cont.

SEQ ID NOS 275, 406, 411 and 404 EVQLVQSGGTVVPQGGTLRLTCAAS/CDR1/WIRQAPGKGLEWVG/CDR2/RVTFSLDTSKSTAYLQMNSLRAEDTAVYYCA/CDR3/WGQGTLLVTVSS	Deleted: :
SEQ ID NOS 276, 402, 415 and 404 EVQLVQSGGTVVPQGGTLRLTCAAS/CDR1/WVRQAPGKGLEWVG/CDR2/RVTISLDTSKSTVYLQMNSLRAEDTAVYYCA/CDR3/WGQGTLLVTVSS	Deleted: :
SEQ ID NOS 277, 406, 416 and 404 QVQLVQSGGGLVQPGGSLRLTCAAS/CDR1/WIRQAPGKGLEWVG/CDR2/RFTFSLDTSKSKAYLQNSLRAEDTAVYYCA/CDR3/WGQGTLLVTVSS	Deleted: :
SEQ ID NOS 278, 406, 417 and 404 QVQLVQSGGTVVPQGGSLRLTCAAS/CDR1/WIRQAPGKGLEWVG/CDR2/RVTFSLDNKSTVYLQMNSLRAEDTAVYYCA/CDR3/WGQGTLLVTVSS	Deleted: :
SEQ ID NOS 279, 402, 418 and 404 QVQLVQSGGTVVPQGGSLRLTCAAS/CDR1/WVRQAPGKGLEWVG/CDR2/RFTISLDTSKNTAYLQNSLRAEDTAVYYCA/CDR3/WGQGTLLVTVSS	Deleted: :
SEQ ID NOS 280, 406, 419 and 404 QVQLVQSGGTVVPQGGSLRLTCAAS/CDR1/WIRQAPGKGLEWVG/CDR2/RVTISLDTSKSQAYLQMNSLRAEDTAVYYCA/CDR3/WGQGTLLVTVSS	Deleted: :
SEQ ID NOS 281, 406, 420 and 404 QVQLVQSGGTVVPQGGSLRLTCAAS/CDR1/WIRQAPGKGLEWVG/CDR2/RVTISLDTSKSTAYLQNSLRAEDTAVYYCA/CDR3/WGQGTLLVTVSS	Deleted: :
SEQ ID NOS 282, 406, 414 and 404 QVQLVQSGGTVVPQGGTLRLTCAAS/CDR1/WIRQAPGKGLEWVG/CDR2/RFTFSLDTSKNTAYLQMNSLRAEDTAVYYCA/CDR3/WGQGTLLVTVSS	Deleted: :

[Some Annotation as for Sheet-13] The Sequence Identifiers Listed Above in Blue Text were added to each of the sequence descriptions and "g"s were removed after the term "SEQ ID NOS."